Organic compounds -- part of the class 532-570 series – Organic compounds – Unsubstituted hydrocarbyl chain between the ring and the -c-...
Reexamination Certificate
2006-09-19
2006-09-19
Kifle, Bruck (Department: 1624)
Organic compounds -- part of the class 532-570 series
Organic compounds
Unsubstituted hydrocarbyl chain between the ring and the -c-...
Reexamination Certificate
active
07109326
ABSTRACT:
Halo-alkoxycarbonyl derivatives are provided as prodrug moieties for pharmaceutical agents containing a basic or polar nitrogen containing functionality. The prodrugs are provided as pharmaceutical compositions as well as in methods of treatment.
REFERENCES:
patent: 4046887 (1977-09-01), Paris et al.
patent: 4381307 (1983-04-01), Sloan
patent: 4760057 (1988-07-01), Alexander et al.
patent: 4851426 (1989-07-01), Ladkani et al.
patent: 5001115 (1991-03-01), Sloan
patent: 5446056 (1995-08-01), Wityak et al.
patent: 5466811 (1995-11-01), Alexander
patent: 5478945 (1995-12-01), Sato et al.
patent: 5554643 (1996-09-01), Horwell et al.
patent: 5576444 (1996-11-01), Himmelsbach et al.
patent: 5589588 (1996-12-01), Toce
patent: 5599793 (1997-02-01), Chirgadze et al.
patent: 529858 (1993-03-01), None
patent: 540051 (1993-05-01), None
patent: 540574 (1993-05-01), None
patent: 743320 (1996-11-01), None
patent: WO 93/08174 (1993-04-01), None
patent: WO 94/17817 (1994-08-01), None
patent: WO 95/04057 (1995-02-01), None
patent: WO 95/13274 (1995-05-01), None
patent: WO 95/14682 (1995-06-01), None
patent: WO 95/29189 (1995-11-01), None
patent: WO 95/35312 (1995-12-01), None
patent: WO 95/35313 (1995-12-01), None
patent: WO 96/11697 (1996-04-01), None
patent: WO 96/24609 (1996-08-01), None
patent: WO 96/32110 (1996-10-01), None
Alexander, J. et al., “(Acyloxy)alkyl Carbamates as Novel Bioreversible Prodrugs for Amines: Increased Permeation through Biological Membranes”Journal of Medicinal Chemistry31:318-322 (1988).
Aoki, T. et. al., “The Anti-Platelet and Anti-Thrombotic Effects of FK633, A Peptide-Mimetic GPIIB/IIA Antagonist”Thrombosis Research81(4) :439-450 (1996).
Barker, P. L. et al., “Cyclic RGD Peptide Analogues as Antiplatelet Antithrombotics”Journal Medicinal Chemistry35:2040-2048 (1992).
Bercz, J. P. et al., “Repeated-Dose and Subchronic Toxicity Studies of 2,2,2-Trichloroethanol in Sprague-Dawley Rats”Journal of the American College of Toxicology10(2) :223-232 (1991).
Betrand, J. A. et al., “Inhibition of Trypsin and Thrombin by Amino(4-amidinophenyl)methanephosphonate Diphenyl Ester Derivatives: X-ray Structures and Molecular Models”Biochemistry35:3147-3155 (1996).
Bondinell, W. E. et al., “Design of a Potent and orally Active Nonpeptide Platelet Fibrinogen Receptor (GPIIb/IIIa) Antagonist”Bioorganic&Medicinal Chemistry2(9) :897-908 (1994).
Bovy, P. R. et al., “Design of Orally Active, Non-Peptide Fibrinogen Receptor Antagonists. An Evolutionary Process from the RGD Sequence to Novel Anti-Platelet Aggregation Agents”Boorganic&Medicinal Chemistry2(9) :881-895 (1994).
Carteaux, J-P et al., “RO 44-9883, a New Non-Peptidic GPIIb-GPIIIa Antagonist Prevents Platelets Loss in a Guinea Pig Model of Extracorporeal Circulation”Thrombosis and Haemostasis70(5) :817-821 (1993).
Cook, N.S. et al., “Platelet Aggregation and Fibrinogen Binding in Human, Rhesus Monkey, Guinea-Pig, Hamster and Rat Blood: Activiation by ADP and a Thrombin Receptor Peptide and Inhibition by Glycoprotein IIb/IIIa Antagonists”Thrombosis and Haemostasis70(3) :531-539 (1993).
Cox, D. et al., “Pentamidine Is a Specific, Non-Peptide, GPIIb/IIIa Antagonist”Thrombosis and Haemostasis75(3) :503-9 (1996).
Dickneite, G. et al., “Pharmacological Characterization of a New 4-Amidinophenyl-Alanine Thrombine-Inhibitor (CRC 220)”Thrombosis Research77(4) :357-368 (1995).
Eldred, C. D. et al., “Orally Active Non-Peptide Fibrinogen Receptor (GpIIb/IIIa) Antagonists: Identification of 4- [4- [4- (Aminoimino-methyl)phenyl]-1-piperazinyl]-1-piperidineacetic Acid as a Long-Acting, Broad-Spectrum Antithrombotic Agent” Journal of Medicinal Chemistry 37:3882-3885 (1994).
Frederick, L. G. et al., “The Protective Dose of the Potent GpIIIb/IIIa Antagonist SC-54701A Is Reduced When Used in Combination With Aspirin and Heparin in a Canine Model of Coronary Artery Thrombosis”Circulation93(1) :129-134 (1996).
Greene, T.W.Protective Groups in Organic Synthesis, John Wiley & sons pp. 218-224 (1981).
Hara, T. et al., “DX-9065a, a New Synthetic, Potent Anticoagulant and Selective Inhibitor for Factor Xa”Thrombosis and Haemostasis71(3) :314-319 (1994).
Hodohara, K. et al., “Amidinonaphthol derivatives directly inhibit the ligand binding on platelet glycoprotein IIb-IIIa”Pathophysiology2:145-151 (1995).
Mack, H. et al., “Design, Synthesis and Biological Activity of Novel Rigid Amidino-Phenylalanine Derivatives as Inhibitors of Thrombin”Journal of Enzyme Inhibition9:73-86 (1995).
McDowell et al., “From Peptide to Non-Peptide. 1. The Elucidation of a Bioactive Conformation of the Arginine-Glycine-Aspartic Acid Recognition Sequence”J. Am. Chem. Soc. 116:5069-5076 (1994).
McDowell et al., “From Peptide to Non-Peptide. 2. The de Novo Design of Potent, Non-Peptidal Inhibitors of Platelet Aggregation Based on a Benzodiazepinedione Scaffold”J Am Chem Soc116:5077-5083 (1994).
McDowell, R. S. et al., “Structural Studies of Potent Constrained RGD Peptides”Journal of the American Chemical Society114 (24) :9245-9253 (1992).
Olivero et al., “Design, Synthesis and Evaluation of Oral GP IIB/IIIA Antagonists: A Prodrug Approach”Abstracts of Papers of the American Chemical Society(Abstract #129; Poster presented at the 212th ACS National Meeting held at Orlando, FL on Aug. 25-29, 1996 is attached.) 212(Pt. 1) (1996).
Packham, M. A., “Role of platelets in thrombosis and hemostasis”Canadian Journal of Physiology and Pharmacology72:278-284 (1994).
Rubas et al., “The Effect of Chemical Modifications on Octanol/Water Partition (Log D) and Permeabilities Across Caco-2 Monolayers”Adv. Drug Delivery Rev. 23(1-3) :157-162 (1997).
Saari, W. S. et al., “Cyclization-Activated Prodrugs. Basic Carbamates of 4-Hydroxyanisole”Journal of Medicinal Chemistry33:97-101 (1990).
Sall, D. J. et al., “Platelet Glycoprotein IIb-IIIa Receptor (GpIIb-IIIa) Antagonists Derived from Aminidinoindoles”Bioorganic&Medicinal Chemistry Letters6(1) :81-86 (1996).
Saulnier, M. G. et al., “An Efficient Method for the Synthesis of Guanidino Prodrugs”Bioorganic&Medicinal Chemistry Letters4(16) :1985-1990 (1994).
Sturzebecher, J. et al., “Synthetic Inhibitors of Bovine Factor Xa and Thrombin Comparison of Their Anticoagulant Efficiency”Thrombosis Research54:245-252 (1989).
Verbiscar et al., “Carbamate Ester Latentiation of Physiologically Active Amines”Journal of Medicinal Chemistry13(6) :1176-1179 (1970).
Xue, C-B et al., “Design, Synthesis and In Vitro Activates of a Series of Benzimidazole/Benzoxazole Glycoprotein IIb/IIIa Inhibitors”Bioorganic&Medicinal Chemistry Letters6(3) :339-344 (1996).
Blackburn Brent
Olivero Alan G.
Robarge Kirk
Evans David W
Genentech Inc.
Kifle Bruck
LandOfFree
Halo-alkoxycarbonyl prodrugs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Halo-alkoxycarbonyl prodrugs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Halo-alkoxycarbonyl prodrugs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3596152